ITI Pharma and Healthcare Fund Regular Growth
Medium
Risk
Equity
Other
+
0.00
%
0.00
%
3Y annualised
+
0.16
%
0.16
%
1D
1M
6M
1Y
3Y
All
Fund size
157
NAV:
Mar 7, 2024
13.4294
Sector
Tech
Type
Equity
Launched
Nov 2021
Min Investment
5000
Expense Ratio
2
Risk
Medium
Portfolio allocation
Top 10 Holdings
% Value
Sun Pharmaceuticals Industries Ltd
16.63
%
Lupin Ltd
6.15
%
Dr Reddy's Laboratories Ltd
5.74
%
Max Healthcare Institute Ltd Ordinary Shares
5.43
%
Mankind Pharma Ltd
4.88
%
Suven Pharmaceuticals Ltd
4.33
%
Apollo Hospitals Enterprise Ltd
3.9
%
Divi's Laboratories Ltd
3.72
%
Zydus Lifesciences Ltd
3.69
%
Cipla Ltd
3.32
%
Expense ratio, exit load and tax
Expense Ratio:
2
%
Inclusive of GST
Exit load
Exit load of 1.0% if redeemed within 12.0 Months, 0.0 % if redeemed after 12.0 Months.
Tax implication
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
Fund house & investment objective
ITI Pharma and Healthcare Fund Regular Growth
More details
Investment objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Scheme Information Document
Mutual Fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not an indicator of future returns.
Calculate returns
One-time
Monthly SIP
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
* Returns are calculated as per lifetime average per annum returns of the fund.
Calculate returns
Monthly SIP
One-time
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
